Evangelisches Krankenhaus Bethesda Monchengladbach Gemeinnutzige GmbH

At Evangelisches Krankenhaus Bethesda Monchengladbach Gemeinnutzige GmbH, the Breast Center is focused on oncology research, with trials centered on breast cancer and related neoplasms. The studies explore how to improve treatment outcomes, understand disease behavior, and support better long-term care for patients.

• Research in advanced HER2-negative, hormone receptor-positive breast cancer, including efforts to evaluate treatment effectiveness in the first-line setting
• Studies in high-risk, node-positive early-stage breast cancer, aimed at testing whether adding new therapy can improve disease control after surgery
• Work in HER2-positive early-stage breast cancer, with a focus on recurrence prevention and improving patient health status over time

The site’s clinical trials are mainly designed to assess survival, recurrence risk, and overall safety and efficacy of treatment strategies for different forms of breast cancer.

Clinical research at this health care institution includes studies for patients with advanced breast cancer, especially those with HER2-negative, hormone receptor-positive disease. These trials are intended to better understand how treatments perform in everyday clinical use and how resistance to therapy may develop.

• Investigation of progression-free survival and overall survival in advanced disease
• Analysis of treatment response patterns in patients receiving modern breast cancer therapies
• Research into the biological and clinical factors that may influence therapy effectiveness and resistance

This area of research helps refine care for people with more advanced disease by supporting more effective and better-targeted treatment decisions.

The Breast Center also contributes to trials in previously untreated HER2-positive early-stage breast cancer. These studies aim to improve outcomes after diagnosis by examining whether treatment approaches can reduce the chance of recurrence while maintaining quality of life.

• Evaluation of recurrence-free interval in early-stage disease
• Assessment of global health status after treatment begins
• Focus on improving treatment effectiveness while supporting patient well-being

Research in this field is especially important for identifying better strategies for patients with HER2-positive breast cancer at an early stage, where timely and effective treatment can make a major difference.